Overview | Agenda/Faculty Materials | Promotional Opportunities
Administration | Speaking Proposals | Log In | Past Conferences | Contact Us | Home


Evolving developments in law and regulation applied to the pharmaceutical industry, public opinion on standards of ethical behavior and the global economic situation make this a challenging time to be a compliance professional or legal counsel responsible for ensuring adherence to applicable laws, regulations and codes of practice within our industry. Worldwide, industry leaders emphasize the importance of ethical behavior, reputation and compliance activities in forming a cornerstone for building trust by government and the public in the global pharmaceutical enterprise. The Pharmaceutical Compliance Forum International Pharma Congress brings together senior global compliance and ethics professionals and legal counsel from the European Union (EU), Central and Eastern Europe (CEE) and Middle East and Africa (MEA) to share experiences and best practices to clarify these challenges and discuss potential responses to them.

Across Europe, the Middle East and Africa, regulators are increasingly active at both national and regional levels. In the USA, aggressive FCPA enforcement and the new Federal Sunshine Act are beginning to have a significant impact across the pharmaceutical industry in EU, CEE and MEA. Emerging markets and notably Russia, CIS and Turkey are attracting more direct investment to address growing unmet medical needs. The growing importance of new regulations like the UK Bribery Act or the Anti-Corruption bills in Russia, in conjunction with increasing FCPA enforcement, indicate that authorities are now going to deeply influence business practices in these regions. Local trade associations in those markets are starting to close the gap with their peers from more advanced markets in addressing ethics and compliance issues.

The Congress is keynoted by David Brennan, Chief Executive Officer, AstraZeneca and President, International Federation of Pharmaceutical, Manufacturers and Associations (IFPMA). Other keynote speakers include representatives of EFPIA, ETHIC Intelligence International, FARMAINDUSTRIA, the Institute of Business Ethics, the UK Prescription Medicines Code of Practice Authority and the OECD. Panel discussions will focus on disclosure and transparency; trust, reputation and the public perception of the global pharmaceutical enterprise; and the EFPIA Leadership Statement: one year's experience. There also will be track discussions on European Union compliance update; Central and Eastern Europe compliance update; Middle East and Africa compliance update; global compliance audits and monitoring; FCPA and global anticorruption; global transparency, disclosure and aggregate spend; and global compliance case studies. Pharmaceutical compliance leaders will share their views in a closing session on envisioning pharma compliance in 2015: a compliance crystal ball session.

If you want to find out how to manage compliance in these challenging times, the PCF International Pharma Congress will give you the information that you need.

  • Pharmaceutical Manufacturers
  • Generic Pharmaceutical Manufacturers
  • Site Management Organizations
  • Clinical Research Organizations
  • Management Companies
  • Wholesale, Retail, Mail Order and Internet Pharmacies
  • Health Care Regulators and Policy Makers
  • Pharmaceutical and Health Care Executives and Board Members
  • Regulatory and Compliance Professionals
  • Medical Directors
  • Physicians
  • Pharmacists

  • Food and Drug Law Attorneys
  • Health Care Attorneys and In-house Counsel
  • Compliance Officers
  • Privacy Officers
  • Ethics Officers and Corporate
  • Social Responsibility Personnel
  • Pharmaceutical Consultants
  • Investment Bankers
  • Venture Capitalists
  • Health Services Researchers and Academics
  • Auditors
  • Promotion Signatories/Approvers
  • Risk Management Personnel

Pharmaceutical Compliance Forum:

The Pharmaceutical Compliance Forum (PCF), www.PharmaComplianceForum.org, is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early 1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field, and sponsor a two-day international compliance congress in the Spring and a three-day US compliance congress each Fall.

Co Chairs
Kelly B. Freeman, PhD
Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN, USA
Dominique Laymand, Esq.
Executive Director Compliance & Ethics EMEA (Europe, Middle-East, Africa, Russia and Turkey), Bristol-Myers Squibb, Paris, France
Roeland Van Aelst
Vice President EMEA & Canada, Office Health Care Compliance & Privacy, Johnson & Johnson, Brussels, Belgium

Ted Acosta, Esq.
Principal, Ernst & Young LLP, Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services, New York, NY, USA and Paris, France

Ann Beasley Bacon
Global Compliance Officer, Novartis Pharma AG, Basel, Switzerland

Wayne Baker
Senior Vice President, Advanced Health Media LLC, Bridgewater, NJ, USA

Karie Jo Barwind, Esq.
Area Director Business Practices, Western Europe, Abbott Laboratories, Rungis Cedex, France

Bulent Becan, M.Sc.ChE
Managing Partner, Atuva Management Consultancy & Trade Ltd., Ethics Consultant to AIFD (Research-Based Pharmaceutical Companies Association), Consultant to IFPMA, Istanbul, Turkey

John T. Bentivoglio, Esq.
Partner, Skadden Arps LLP, Washington, DC, USA

Gabor Danielfy
Vice-President & Global Compliance Officer, Sanofi-aventis, Paris, France

Pierre E. Dupourque
Regional Compliance Director, Corporate Compliance, International Investigations and Programs, Pfizer Inc, Mannheim, Germany

Sue Egan
Director, Sue Egan Associates Limited, Former Vice President Compliance, AstraZeneca, London, UK

Sameh Farag
Regional Compliance Director, MEA, Merck, Member of the Phrma MEA Ethics Board, Dubai, United Arab Emirates
Gerard Geneen
Vice President, Compliance Officer, Pharma Europe, GlaxoSmithKline, Brentford, Middlesex, UK

Gary F. Giampetruzzi, Esq.
Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc, New York, NY, USA

Keith M. Korenchuk, JD, MPH
Partner, Arnold & Porter LLP, Washington, DC, USA

Maxine Nogard
Senior Director, Global Corporate Compliance, Biogen Idec Inc., Weston, MA, USA

Brian Riewerts
Partner, Global Pharmaceuticals and Life Sciences, PricewaterhouseCoopers LLP, Baltimore, MD, USA

Jeffrey Rosenbaum
Global Head, Ethics & Compliance, Novartis Oncology, Florham Park, NJ, USA

Guillaume Roussel
Vice President, Compliance Solutions EMEA, Cegedim Relationship Management, Paris, France

Joseph B. Tompkins, Jr.
Partner, Sidley Austin LLP, Former Deputy Chief of the Fraud Section, Criminal Division of the United States Department of Justice, Washington, DC, USA

Paul B. Woods, BPharm, MA, MRPharmS
Independent Consultant, Former Global Compliance Policy Director, AstraZeneca, Macclesfield, Cheshire, UK

Elisabethann Wright, Esq.
Partner, Hogan Lovells International LLP, Former Senior Legal Officer and Hearing Officer, EFTA Surveillance Authority, Brussels, Belgium

Overview | Agenda/Faculty Materials | Promotional Opportunities
Administration | Speaking Proposals | Log In | Past Conferences | Contact Us | Home

© Health Care Conference Administrators
Contact Webmaster